Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Precision BioSciences has received upfront cash payment and equity investment totalling $17.5m from TG Therapeutics for an exclusive licence to develop Azercabtagene Zapreleucel (azer-cel).
Subscribe to our email newsletter
Earlier in January, Precision announced the completion of a strategic deal with TG Therapeutics for the exclusive licence to develop azer-cel for autoimmune diseases and other non-cancer indications.
This deal marks the first in a series of payments to Precision in upfront and potential near-term payments.
In return for the worldwide rights to azer-cel for autoimmune applications as well as non-cancer indications, Precision received $7.5m in upfront payment.
The upfront payments include cash and acquisition of 2,920,816 shares of Precision common stock by TG Therapeutics at $0.77 price per share. This stock value is a 100% premium over the 30-day volume-weighted average price before the acquisition.
Precision is also entitled to receive a further equity investment of $2.5m within 11 months, at a 100% premium to the 30-day volume-weighted average price prior to the investment.
Furthermore, on meeting specific near-term clinical milestones, Precision will be eligible to receive another $7.5m.
The agreement also entitles Precision to up to $288m in milestone payments, along with royalty payments on net product sales ranging from high-single-digit to low-double-digit percentages.
Precision anticipates that the recent payments from the azer-cel deals, combined with its current cash, anticipated operational receipts, continued fiscal and operational discipline and the availability of its at-the-market facility, will extend its cash runway into the first half of 2026.
The company plans to execute activities including Phase I clinical readouts for its wholly-owned programmes during this time period.
